According to Roche sales of Tamiflu[oseltamivir phosphate] tripled to 1 billion Swiss francs ($931 million) since the outbreak of swine flu in April spurred by retail sales and the stockpiling of the drug by governments and corporations. Roche plans to produce 400 million packs annually by start of 2010 a huge increase given that for the last five years it has only produced 300 million packs in total. Leading oncology medications, Pegasys [peginterferon alfa-2a] for hepatitis and Lucentis [ranibizumab injection] for ophthalmology were also causing large sales growth in the pharma division. The $46.8 billion acquisition of Genentech will yield the company savings of 1 billion Swiss francs ($940 million) a year by 2011.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지